Liver Damage, Inflammation, and Enhanced Tumorigenesis after Persistent mTORC1 Inhibition
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Summary Obesity can result in insulin resistance, hepatosteatosis and non-alcoholic steatohepatitis (NASH) and increases liver cancer risk. Obesity-induced insulin resistance depends, in part, on chronic activation of mammalian target of rapamycin complex 1 (mTORC1), which also occurs in human and mouse hepatocellular carcinoma (HCC), a frequently fatal liver cancer. Correspondingly, mTORC1 inhibitors have been considered as potential NASH and HCC treatments. Using a mouse model in which high fat diet enhances HCC induction by the hepatic carcinogen DEN we examined whether mTORC1 inhibition attenuates liver inflammation and tumorigenesis. Notably, rapamycin treatment or hepatocyte-specific ablation of the specific mTORC1 subunit Raptor resulted in elevated interleukin 6 (IL-6) production, activation of STAT3 and enhanced HCC development, despite a transient reduction in hepatosteatosis. These results suggest that long term rapamycin treatment, which also increases IL-6 production in humans, is unsuitable for prevention or treatment of obesity-promoted liver cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults
Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021423 · Cited by 7,696 · cited 3×
“This interest hasbeenparticularly high in HCC, because in addition to genetic loss of negative regulators that function as tumor suppressors, mTORC1 is activated in response to obesity, which greatly enhances HCC risk in men (Calle et al., 2003) and mice (Park et al., 2010).”
Autophagy regulates lipid metabolism
Singh, R., Kaushik, S., Wang, Y., Xiang, Y., Novak, I., Komatsu, M., Tanaka, K., Cuervo, A. M., & Czaja, M. J. (2009) · Nature · doi:10.1038/nature07976 · Cited by 3,975
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., Flurkey, K., Nadon, N. L., Wilkinson, J. E., Frenkel, K., Carter, C. S., et al. (2009) · Nature · doi:10.1038/nature08221 · Cited by 3,766 · cited 2×
“Such results stand in marked contrast to reports of rapamycininduced lifespan extension (Harrison et al., 2009; Johnson et al., 2013), although follow-up studies discovered several adverse effects of long-term rapamycin use (Lamming et al.”
Defining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833
Activation of a metabolic gene regulatory network downstream of mTOR complex 1
Düvel, K., Yecies, J. L., Menon, S., Raman, P., Lipovsky, A. I., Souza, A. L., Triantafellow, E., Ma, Q., Gorski, R., Cleaver, S., et al. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.06.022 · Cited by 2,020 · cited 2×
“Accordingly, rapalogs are potent suppressors of cellular proliferation and growth and can revert several metabolic disorders, such as insulin resistance and hepatosteatosis, caused by persistent mTORC1 activation after hypernutrition (Cornu et al., 2013; Düvel et al., 2010).”
Ras, PI(3)K and mTOR signalling controls tumour cell growth
Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019
Park, E. J., Lee, J. H., Yu, G.-Y., He, G., Ali, S. R., Holzer, R. G., Österreicher, C. H., Takahashi, H., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2009.12.052 · Cited by 1,764 · cited 2×
“This interest hasbeenparticularly high in HCC, because in addition to genetic loss of negative regulators that function as tumor suppressors, mTORC1 is activated in response to obesity, which greatly enhances HCC risk in men (Calle et al., 2003) and mice (Park et al., 2010).”
Self-citationmTOR is a key modulator of ageing and age-related disease
Johnson, S. C., Rabinovitch, P. S., & Kaeberlein, M. (2013) · Nature · doi:10.1038/nature11861 · Cited by 1,676 · cited 4×
“Such results stand in marked contrast to reports of rapamycininduced lifespan extension (Harrison et al., 2009; Johnson et al., 2013), although follow-up studies discovered several adverse effects of long-term rapamycin use (Lamming et al.”
InfluentialmTOR and cancer: insights into a complex relationship
Sabatini, D. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1974 · Cited by 1,322
Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity
Lamming, D. W., Ye, L., Katajisto, P., Goncalves, M. D., Saitoh, M., Stevens, D. M., Davis, J. G., Salmon, A. B., Richardson, A., Ahima, R. S., et al. (2012) · Science · doi:10.1126/science.1215135 · Cited by 1,199
Cited by
MASLD: a systemic metabolic disorder with cardiovascular and malignant complications
Targher, G., Byrne, C. D., & Tilg, H. (2024) · Gut · doi:10.1136/gutjnl-2023-330595 · Cited by 897
Metabolic Control of Longevity
López-Otín, C., Galluzzi, L., Freije, J. M. P., Madeo, F., & Kroemer, G. (2016) · Cell · doi:10.1016/j.cell.2016.07.031 · Cited by 753
“…of AMPK in satellite cells is responsible for reduced skeletal muscle regeneration, a condition that might contribute to age-associated sarcopenia (Fu et al., 2016), whereas chronic activation of MTORC1 may contribute to the hepatic steatosis that often accompanies aging (Umemura et al., 2014).”
BackgroundRisk factors and prevention of hepatocellular carcinoma in the era of precision medicine
Fujiwara, N., Friedman, S. L., Goossens, N., & Hoshida, Y. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.09.016 · Cited by 659
A gp130–Src–YAP module links inflammation to epithelial regeneration
Taniguchi, K., Wu, L.-W., Grivennikov, S. I., de Jong, P. R., Lian, I., Yu, F.-X., Wang, K., Ho, S. B., Boland, B. S., Chang, J. T., et al. (2015) · Nature · doi:10.1038/nature14228 · Cited by 633
Self-citationUmemura, A., He, F., Taniguchi, K., Nakagawa, H., Yamachika, S., Font-Burgada, J., Zhong, Z., Subramaniam, S., Raghunandan, S., Duran, A., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.04.006 · Cited by 463
Self-citationFinkin, S., Yuan, D., Stein, I., Taniguchi, K., Weber, A., Unger, K., Browning, J. L., Goossens, N., Nakagawa, S., Gunasekaran, G., et al. (2015) · Nature Immunology · doi:10.1038/ni.3290 · Cited by 433
Self-citationZhang, Q., Jeppesen, D. K., Higginbotham, J. N., Graves-Deal, R., Trinh, V. Q., Ramirez, M. A., Sohn, Y., Neininger, A. C., Taneja, N., McKinley, E. T., et al. (2021) · Nature Cell Biology · doi:10.1038/s41556-021-00805-8 · Cited by 419
Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies
Musso, G., Cassader, M., & Gambino, R. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.3 · Cited by 412
mTORC2 Promotes Tumorigenesis via Lipid Synthesis
Guri, Y., Colombi, M., Dazert, E., Hindupur, S. K., Roszik, J., Moes, S., Jenoe, P., Heim, M. H., Riezman, I., Riezman, H., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.11.011 · Cited by 407
Self-citationp62 in Cancer: Signaling Adaptor Beyond Autophagy
Moscat, J., Karin, M., & Diaz-Meco, M. T. (2016) · Cell · doi:10.1016/j.cell.2016.09.030 · Cited by 391
Self-citationAutophagy in liver diseases: A review
Qian, H., Chao, X., Williams, J., Fulte, S., Li, T., Yang, L., & Ding, W.-X. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.100973 · Cited by 373
Targeting cancer-promoting inflammation — have anti-inflammatory therapies come of age?
Hou, J., Karin, M., & Sun, B. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00459-9 · Cited by 366
Self-citationObesity and Cancer: The Oil that Feeds the Flame
Font-Burgada, J., Sun, B., & Karin, M. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.015 · Cited by 356
Self-citationHepatocellular carcinoma: signaling pathways and therapeutic advances
Zheng, J., Wang, S., Xia, L., Sun, Z., Chan, K. M., Bernards, R., Qin, W., Chen, J., Xia, Q., & Jin, H. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02075-w · Cited by 341
The Role of PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma Metabolism
Tian, L.-Y., Smit, D. J., & Jücker, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032652 · Cited by 329
mTOR signaling in cellular and organismal energetics
Albert, V., & Hall, M. N. (2015) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2014.12.001 · Cited by 304
Self-citationEricksen, R. E., Lim, S. L., McDonnell, E., Shuen, W. H., Vadiveloo, M., White, P. J., Ding, Z., Kwok, R., Lee, P., Radda, G. K., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2018.12.020 · Cited by 295
The Upstream Pathway of mTOR-Mediated Autophagy in Liver Diseases
Wang, H., Liu, Y., Wang, D., Xu, Y., Dong, R., Yang, Y., Lv, Q., Chen, X., & Zhang, Z. (2019) · Cells · doi:10.3390/cells8121597 · Cited by 279
Rapamycin Increases Mortality in db/db Mice, a Mouse Model of Type 2 Diabetes
Sataranatarajan, K., Ikeno, Y., Bokov, A., Feliers, D., Yalamanchili, H., Lee, H. J., Mariappan, M. M., Tabatabai-Mir, H., Diaz, V., Prasad, S., et al. (2016) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glv170 · Cited by 65
RBM45 reprograms lipid metabolism promoting hepatocellular carcinoma via Rictor and ACSL1/ACSL4
Wang, C., Chen, Z., Yi, Y., Ding, Y., Xu, F., Kang, H., Lin, K., Shu, X., Zhong, Z., Zhang, Z., et al. (2024) · Oncogene · doi:10.1038/s41388-023-02902-4 · Cited by 42
Hypothalamic orexin prevents non-alcoholic steatohepatitis and hepatocellular carcinoma in obesity
Tsuneki, H., Maeda, T., Takata, S., Sugiyama, M., Otsuka, K., Ishizuka, H., Onogi, Y., Tokai, E., Koshida, C., Kon, K., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111497 · Cited by 21
Sharma, N., Singh, L., Sharma, A., Kumar, A., & Mahajan, D. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107375 · Cited by 16
Hepatocyte β‐catenin loss is compensated by Insulin‐mTORC1 activation to promote liver regeneration
Hu, S., Cao, C., Poddar, M., Delgado, E., Singh, S., Singh‐Varma, A., Stolz, D. B., Bell, A., & Monga, S. P. (2023) · Hepatology · doi:10.1002/hep.32680 · Cited by 11
“Mice with Albumin‐Cre Raptor deletion (RaptorΔLiver) showed delayed LR after PH without impact on survival.[44] However, acute Raptor deletion led to a 100% mortality by 48 h after PH.”
Background
Metadata
- Authors
- Umemura, A., Park, E. J., Taniguchi, K., Lee, J. H., Shalapour, S., Valasek, M. A., Aghajan, M., Nakagawa, H., Seki, E., Hall, M. N., & Karin, M.
- Venue
- Cell Metabolism
- Publisher
- Elsevier BV
- Published
- 2014-07
- Volume
- 20
- Issue
- 1
- Pages
- 133-144
- ISSN
- 1550-4131 (ISSN-L)
- OpenAlex
- W2039935344
- Cited by
- 183
- References
- 13
- FWCI
- 6.69
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.